OCT2 is primarily expressed in the kidney, which might explain low intracellular platinum accumulation following carboplatin treatment of A498 kidney cancer cells and higher levels of accumulation upon treatment with cisplatin or oxaliplatin. Here, SLC22A2 is linked to kidney cancer.